Other
Neoplasm by Morphology
CI-CAN-00000002Explore in graph →
Non-malignant13,325 active trials222 approved drugs2,774 evidence items
- NCIt
- C4741
Loading cancer entity…
Other
CI-CAN-00000002Explore in graph →
Clinical trials
52,671 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06178939 | Effects of Cognitive Intervention Therapy on Postoperative Delirium | not yet recruiting | N/A | 60 | Yonsei UniversityOTHER | 1 | Dec 21, 2023 | clinicaltrials |
| NCT06178211 | Neoadjuvant Adebrelimab Plus Chemotherapy for Resectable ESCC: a Single Arm, Prospective Phase 2 Clinical Trial | not yet recruiting | Phase 2 | 36 | Shanghai Chest HospitalOTHER | 1 | Dec 20, 2023 | clinicaltrials |
| NCT06060847 |
| Liver Resection and Simultaneous Sleeve Gastrectomy for MS-HCC (LIRESS)(LIRESS) |
| not yet recruiting |
| N/A |
| 50 |
| Ospedale V. FazziOTHER |
| 1 |
| Dec 19, 2023 |
| clinicaltrials |
| NCT06109402 | Perioperative Immunotherpay Versus Adjuvant Immunotherapy for Resectable Non-small Cell Lung Cancer | not yet recruiting | Phase 2 | 160 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Dec 19, 2023 | clinicaltrials |
| NCT06175702 | Treatment Protocol for Newky Diagnosed Adult Ph Positive ALL(LALPh2022) | not yet recruiting | — | 150 | PETHEMA FoundationOTHER | 0 | Dec 19, 2023 | clinicaltrials |
| NCT06168357 | Role of Abbreviated MRI in Follow-up of Hepatocellular Carcinoma . | not yet recruiting | — | 55 | Assiut UniversityOTHER | 0 | Dec 13, 2023 | clinicaltrials |
| NCT06121271 | Trial of Lu-177 DOTATATE (Lutathera®) in Unlicensed Indications | not yet recruiting | Phase 2 | 110 | University College, LondonOTHER | 0 | Dec 7, 2023 | clinicaltrials |
| NCT06152978 | A Perioperative Sintilimab and Chemotherapy in Esophageal Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 182 | Fudan UniversityOTHER | 1 | Dec 1, 2023 | clinicaltrials |
| NCT05627115 | Response Adapted Incorporation of Tislelizumab Into the Front-line Treatment of Older Patients With Hodgkin lYmphoma(RATiFY) | not yet recruiting | Phase 2 | 80 | University College, LondonOTHER | 0 | Nov 29, 2023 | clinicaltrials |
| NCT06146777 | Multi-classifier System for Stratifying Stage III Papillary Renal Cell Carcinoma of Receiving Adjuvant Therapy | not yet recruiting | Phase 3 | 468 | First Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 0 | Nov 29, 2023 | clinicaltrials |
| NCT05979857 | Study of SP-3164 in Relapsed or Refractory Non-Hodgkin's Lymphoma | not yet recruiting | Early Phase 1 | 72 | Salarius Pharmaceuticals, LLCINDUSTRY | 0 | Nov 22, 2023 | clinicaltrials |
| NCT06142188 | Relmacabtagene Autoleucel in Hematologic Malignancies | not yet recruiting | — | 150 | Shanghai Ming Ju Biotechnology Co., Ltd.INDUSTRY | 1 | Nov 21, 2023 | clinicaltrials |
| NCT06142617 | A Prospective Study of Pembrolizumab Combining Chemotherapy in Advanced NSCLC Patients With EGFR Exon 21 Point Mutation. | not yet recruiting | Phase 2 | 37 | Peking Union Medical College HospitalOTHER | 1 | Nov 21, 2023 | clinicaltrials |
| NCT06136026 | Integrated Chinese and Western Medicine Specialized Disease Cohort for Colorectal Cancer | not yet recruiting | — | 50,000 | Jiangsu Famous Medical Technology Co., Ltd.INDUSTRY | 0 | Nov 18, 2023 | clinicaltrials |
| NCT06136377 | Evaluation of the Concordance Between Pre-therapy Dosimetry Performed From 68Ga-PSMA-11 Dynamic PET and Post-treatment Dosimetry of 177Lu-PSMA-617 Vectorized Internal Radiotherapy in Patients With Metastatic Prostate Cancer Resistant to Hormonal Castration.(GaLuPro) | not yet recruiting | N/A | 35 | Centre Georges Francois LeclercOTHER | 0 | Nov 18, 2023 | clinicaltrials |
| NCT06133556 | Conditioning Regimen Containing Melphalan and Cladribine for Refractory / Relapsed AML | not yet recruiting | Phase 2 | 237 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Nov 15, 2023 | clinicaltrials |
| NCT06127329 | Efficacy and Safety of BAI Combined With DEB-BACE of EqualSpheres in the Treatment of Advanced NSCLC | not yet recruiting | N/A | 70 | Gang WuOTHER | 1 | Nov 13, 2023 | clinicaltrials |
| NCT06125223 | PABLIXIMAB as Neoadjuvant Therapy for Head and Neck Squamous-cell Carcinoma | not yet recruiting | — | 45 | Xijing HospitalOTHER | 0 | Nov 9, 2023 | clinicaltrials |
| NCT06117644 | The Efficacy of Double-dose Furmonertinib in the Treatment of Patients With Slow Osimertinib-resistant NSCLC | not yet recruiting | — | 30 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 0 | Nov 7, 2023 | clinicaltrials |
| NCT06115733 | Study of Fuquinitinib Combined With Capecitabine First-line Maintenance in the Treatment of Metastatic Colorectal Cancer | not yet recruiting | N/A | 56 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 0 | Nov 3, 2023 | clinicaltrials |
| NCT06112041 | The Prospective Clinical Study of Precision PRaG Therapy in Elderly Patients With Advanced Solid Malignant Tumors (PRaG9.0) | not yet recruiting | Phase 2 | 29 | Second Affiliated Hospital of Soochow UniversityOTHER | 1 | Nov 1, 2023 | clinicaltrials |
| NCT06097455 | First in Human Study of the Infusion of ARI0003 Cells in Relapsed/Refractory to Treatment B-cell Aggressive Lymphoma(CARTD-BG-1) | not yet recruiting | Early Phase 1 | 40 | Fundacion Clinic per a la Recerca BiomédicaOTHER | 1 | Oct 26, 2023 | clinicaltrials |
| NCT05923502 | (CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL) | not yet recruiting | — | 200 | Ruijin HospitalOTHER | 0 | Oct 23, 2023 | clinicaltrials |
| NCT06093165 | RE-irradiation of Diffuse MIdline Glioma paTients(REMIT) | not yet recruiting | N/A | 59 | Rigshospitalet, DenmarkOTHER | 0 | Oct 23, 2023 | clinicaltrials |
| NCT06093568 | Delving Into Participation Trends in Renal Cell Carcinoma Studies | not yet recruiting | — | 500 | Power Life Sciences Inc.INDUSTRY | 1 | Oct 23, 2023 | clinicaltrials |
| NCT06093594 | Investigating Participation Patterns Among Stage IV Melanoma Patients | not yet recruiting | — | 500 | Power Life Sciences Inc.INDUSTRY | 1 | Oct 23, 2023 | clinicaltrials |
| NCT06095167 | Induction Chemotherapy and Immunotherapy Combined Radiotherapy With or Without Concurrent Chemotherapy for Stage III-IVa NPC | not yet recruiting | Phase 3 | 476 | Fujian Cancer HospitalOTHER_GOV | 1 | Oct 23, 2023 | clinicaltrials |
| NCT06089382 | A Study to Evaluate Sintilimab Plus Lenvatinib as Adjuvant Therapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis (PVTT) After Surgical Resection | not yet recruiting | Phase 3 | 104 | Tongji HospitalOTHER | 1 | Oct 18, 2023 | clinicaltrials |
| NCT06086288 | Study of PembrolizumAb combiNeD With Cisplatin or carbOplatin and Etoposide in Treatment naïve Advanced meRkel Cell cArcinoma (MCC)(PANDORA) | not yet recruiting | Phase 2 | 35 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Oct 17, 2023 | clinicaltrials |
| NCT05988697 | Evaluate the Efficacy and Safety of Aspirin in Combination With Trametinib and Dabrafenib | not yet recruiting | — | 36 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 0 | Oct 12, 2023 | clinicaltrials |
| NCT06079723 | A Detailed Look At What Patients Experience In Medullary Thyroid Cancer Clinical Study | not yet recruiting | — | 500 | Power Life Sciences Inc.INDUSTRY | 1 | Oct 12, 2023 | clinicaltrials |
| NCT06066931 | Reconstruction of the Pelvic Floor and Perineal Wound After Rectal ELAPE | not yet recruiting | N/A | 150 | Kuban State Medical UniversityOTHER | 0 | Oct 10, 2023 | clinicaltrials |
| NCT06075238 | Blinatumomab Prevents Recurrence of R/R ALL After Allo-HSCT | not yet recruiting | Phase 2 | 68 | Sichuan UniversityOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT05540275 | Tislelizumab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for Bevacizumab Refractory Recurrent Glioblastoma | not yet recruiting | Phase 2 | 30 | Henan Provincial People's HospitalOTHER | 1 | Oct 6, 2023 | clinicaltrials |
| NCT06070246 | Navigating the Clinical Research Process for Lymphoma | not yet recruiting | — | 500 | Power Life Sciences Inc.INDUSTRY | 1 | Oct 6, 2023 | clinicaltrials |
| NCT06067776 | Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer | not yet recruiting | Phase 1 | 36 | Jonathan RiessOTHER | 1 | Oct 5, 2023 | clinicaltrials |
| NCT04790045 | Lymph Node Microenvironment Modifications in Patients With CLL Treated With Venetoclax-based Regimens(LymBIO) | not yet recruiting | Phase 4 | 30 | Paolo GhiaOTHER | 0 | Oct 3, 2023 | clinicaltrials |
| NCT06062485 | Surufatinib Combined With Toripalimab and AG Regiments for First-line Treatment of Unresectable or Relapsing Metastatic Ampullary Carcinoma | not yet recruiting | Phase 2 | 30 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 0 | Oct 2, 2023 | clinicaltrials |
| NCT06039982 | A Diagnostic Nomogram for Predicting Vaginal Invasion in Cervical Cancer | not yet recruiting | — | 100 | Fujian Cancer HospitalOTHER_GOV | 1 | Sep 26, 2023 | clinicaltrials |
| NCT06055114 | Study on Vaginal Microecology and Cervical Local Immune Function in Patients With Uterine Fibroids of Childbearing Age | not yet recruiting | — | 300 | Lin YuanOTHER | 0 | Sep 26, 2023 | clinicaltrials |
| NCT06049472 | Patient Perspectives in Mantle Cell Lymphoma Clinical Research | not yet recruiting | — | 500 | Power Life Sciences Inc.INDUSTRY | 1 | Sep 22, 2023 | clinicaltrials |
| NCT06049485 | Assessing the Experience of Patients Undergoing Follicular Lymphoma Clinical Research | not yet recruiting | — | 500 | Power Life Sciences Inc.INDUSTRY | 1 | Sep 22, 2023 | clinicaltrials |
| NCT06041490 | Adjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver Transplantation | not yet recruiting | Phase 2 | 88 | Peking Union Medical College HospitalOTHER | 1 | Sep 18, 2023 | clinicaltrials |
| NCT06039033 | Exploring Merkel Cell Carcinoma Clinical Trial Engagement Patterns | not yet recruiting | — | 500 | Power Life Sciences Inc.INDUSTRY | 1 | Sep 15, 2023 | clinicaltrials |
| NCT06039046 | Investigating Engagement Patterns and Participation Trends Among Liposarcoma Patients | not yet recruiting | — | 500 | Power Life Sciences Inc.INDUSTRY | 1 | Sep 15, 2023 | clinicaltrials |
| NCT06028633 | Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC Patients | not yet recruiting | Phase 2 | 28 | Peking University First HospitalOTHER | 1 | Sep 13, 2023 | clinicaltrials |
| NCT06032728 | Multimodal Recurrence Scoring System for Stratifying Stage III Clear Cell Renal Cell Carcinoma of Receiving Adjuvant Treatment | not yet recruiting | N/A | 488 | First Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 0 | Sep 13, 2023 | clinicaltrials |
| NCT03865277 | Individualized Radiation Dose Prescription in HNSCC Based on F-MISO-PET Hypoxia-Imaging(INDIRA-MISO) | not yet recruiting | Phase 2 | 276 | Technische Universität DresdenOTHER | 1 | Sep 11, 2023 | clinicaltrials |
| NCT06029465 | Analyzing Engagement Trends in Rhabdomyosarcoma Clinical Trials | not yet recruiting | — | 500 | Power Life Sciences Inc.INDUSTRY | 1 | Sep 8, 2023 | clinicaltrials |
| NCT06029478 | Understanding Engagement Trends in Chondrosarcoma Clinical Trials | not yet recruiting | — | 500 | Power Life Sciences Inc.INDUSTRY | 1 | Sep 8, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Dec 21, 2023source: clinicaltrials